EpiBiologics closed a $107 million Series B to advance its EpiTAC platform and first-in-human candidate EPI-326, a bispecific antibody designed to degrade tumor-surface proteins such as mutant EGFR. The round included participation from GV (Google Ventures), Johnson & Johnson’s venture arm and other major life-science investors. The company plans to start clinical testing in the first half of 2026 in relapsed or refractory non-small-cell lung cancer and head-and-neck cancer populations. EpiBiologics’ EpiTACs use a targeted-degradation mechanism to shuttle cell-surface targets to lysosomes for disposal, aiming to deliver selective tumor clearance while sparing normal tissue. The financing and high-profile backers underscore investor conviction in targeted protein degradation beyond small molecules, and in antibody-based modalities that can be combined with existing cancer therapies.